Epitogenesis, Inc.
EpitoGenesis, Inc. is a biotechnology company established in 2008, focused on designing and developing all-natural immune-enhancing adjuvants and delivery systems for prophylactic and therapeutic vaccines with an emphasis on safety. Their mission is to create efficacious vaccines that eliminate vaccination side effects and improve immune responses, leveraging patented technology based on synergy between dietary supplement molecules. The company has received multiple SBIR awards, has a team of field experts including Nobel laureates and university professors, and actively engages in research, collaborations, and publications to advance vaccine technology.
Industries
Nr. of Employees
small (1-50)
Epitogenesis, Inc.
277 Bendix Rd. Ste 550 Virginia Beach, VA 23452
Patents
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US-10561720-B2
View Details
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US-10561720-B2
View DetailsProducts
Immune-enhancing adjuvant nanoemulsion
A chemically defined formulation composed of select vitamins and naturally occurring polyphenols produced as an oil-in-water nanoemulsion for use as a vaccine adjuvant or dietary supplement to modulate immune responses.
Immune-enhancing adjuvant nanoemulsion
A chemically defined formulation composed of select vitamins and naturally occurring polyphenols produced as an oil-in-water nanoemulsion for use as a vaccine adjuvant or dietary supplement to modulate immune responses.
Services
Partnership-based projects with research institutes to develop vaccine candidates using nutraceutical adjuvant formulations and mucosal delivery strategies.
Preclinical testing services in murine models to assess antigen-specific immune responses following mucosal and systemic vaccination with candidate formulations.
Consultation on mucosal vaccination strategies, route selection, and adjuvant safety profiling based on published reviews and internal research.
Partnership-based projects with research institutes to develop vaccine candidates using nutraceutical adjuvant formulations and mucosal delivery strategies.
Preclinical testing services in murine models to assess antigen-specific immune responses following mucosal and systemic vaccination with candidate formulations.
Consultation on mucosal vaccination strategies, route selection, and adjuvant safety profiling based on published reviews and internal research.
Expertise Areas
- Vaccine adjuvant development
- Mucosal immunology and mucosal vaccine delivery
- Nanoemulsion formulation
- Preclinical immunogenicity testing (murine models)
Key Technologies
- Oil-in-water nanoemulsion formulation
- Nutraceutical-based adjuvant formulations (vitamins and polyphenols)
- Mucosal vaccine delivery routes (oral, vaginal, rectal)
- Preclinical murine immunogenicity models
News & Updates
EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to develop a vaccine against vaginal transmission of Chlamydia trachomatis, using their proprietary Nutritive Immune-enhancing Delivery System, in collaboration with Dr. Deborah Dean at Children’s Hospital Oakland Research Institute. The grant is for two years and the monetary award is $600,000.
EpitoGenesis enters into an agreement with Children’s Hospital Oakland Research Institute on a collaborative project to develop a vaccine against sexual transmission of Chlamydia trachomatis.
EpitoGenesis, Inc. is awarded an NIH grant to further explore the NIDS technology for HIV vaccines.
EpitoGenesis begins collaboration with Dr. Julia Hurwitz at St. Jude’s Hospital on an HIV vaccine project and submission of a
EpitoGenesis Publication: Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Yu M, Vajdy M. Expert Opin Biol Ther.
EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses.
EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to develop a vaccine against vaginal transmission of Chlamydia trachomatis, using their proprietary Nutritive Immune-enhancing Delivery System, in collaboration with Dr. Deborah Dean at Children’s Hospital Oakland Research Institute. The grant is for two years and the monetary award is $600,000.
EpitoGenesis enters into an agreement with Children’s Hospital Oakland Research Institute on a collaborative project to develop a vaccine against sexual transmission of Chlamydia trachomatis.
EpitoGenesis, Inc. is awarded an NIH grant to further explore the NIDS technology for HIV vaccines.
EpitoGenesis begins collaboration with Dr. Julia Hurwitz at St. Jude’s Hospital on an HIV vaccine project and submission of a
EpitoGenesis Publication: Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Yu M, Vajdy M. Expert Opin Biol Ther.
EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses.